Physician profile
Thomas S Cerasaro
NPI 1295765402
$6,254.81
in general payments reported to CMS, 2019-2025
34 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,971 · 2020: $612 · 2021: $874 · 2022: $1,013 · 2023: $542 · 2024: $829 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,328.91 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $1,118.17 | 2019-2020 | |
| Boston Scientific Corporation | $749.64 | 2019-2025 | Ams 700, Rezum Generator, Lumenis Pulse 100h |
| Endo Pharmaceuticals INC. | $418.20 | 2019-2023 | Xiaflex |
| Astellas Pharma US INC | $367.64 | 2019-2021 | |
| Coloplast Corp | $315.15 | 2020-2024 | Speedicath |
| Healthtronics Stone Solutions, LLC | $311.26 | 2019-2021 | |
| Procept Biorobotics Corporation | $203.36 | 2022-2024 | Aquabeam System |
| Medtronic, INC. | $172.10 | 2022-2024 | Illumisite |
| Sumitomo Pharma America, INC. | $168.03 | 2023-2024 | Gemtesa, Orgovyx |
| Dornier Medtech America, INC | $151.20 | 2020 | |
| Janssen Biotech, INC. | $133.21 | 2019-2025 | Erleada |
| Axonics, INC. | $121.89 | 2024 | Bulkamid, Axonics |
| Convatec INC. | $88.68 | 2020-2022 | |
| Medtronic USA, INC. | $88.26 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $64.94 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $61.98 | 2019-2020 | |
| Urovant Sciences INC | $60.34 | 2022 | |
| Rochester Medical Corporation | $57.70 | 2021-2022 | |
| Tolmar, INC. | $45.67 | 2024-2025 | Jatenzo, Eligard |
| Zyla Life Sciences, INC. | $28.76 | 2019-2020 | |
| Abbvie INC. | $26.20 | 2019 | |
| Ambu INC. | $25.58 | 2021-2022 | |
| Abc Home Medical Supply, INC. | $24.46 | 2022 | |
| Blue Earth Diagnostics | $20.50 | 2021 | |
| Cook Medical LLC | $16.38 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.04 | 2021 | |
| Photocure INC | $15.80 | 2023 | Cysview |
| Acerus Pharmaceuticals Corporation | $15.39 | 2022 | |
| Abbott Laboratories | $15.06 | 2019 | |
| Antares Pharma, INC. | $13.10 | 2022 | |
| Dentsply Ih INC. | $11.21 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cerasaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.